BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Hold” by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received a consensus recommendation of “Hold” from the twelve research firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $9.07.

Several research analysts have recently weighed in on the stock. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. Jefferies Financial Group decreased their target price on shares of BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 22nd. ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 22nd. Finally, JMP Securities reduced their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, May 23rd.

In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 11,750 shares of the stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $7.81, for a total transaction of $91,767.50. Following the transaction, the insider now directly owns 137,176 shares in the company, valued at approximately $1,071,344.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas R. Staab II sold 7,500 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $8.81, for a total transaction of $66,075.00. Following the transaction, the insider now owns 140,176 shares in the company, valued at $1,234,950.56. The disclosure for this sale can be found here. Insiders have sold a total of 75,000 shares of company stock worth $583,298 over the last quarter. 5.20% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of the company. JGP Global Gestao de Recursos Ltda. lifted its position in shares of BioCryst Pharmaceuticals by 8.5% in the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 25,742 shares of the biotechnology company’s stock worth $210,000 after buying an additional 2,018 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 4.9% in the 1st quarter. AQR Capital Management LLC now owns 46,870 shares of the biotechnology company’s stock worth $382,000 after buying an additional 2,185 shares during the last quarter. Legal & General Group Plc lifted its position in shares of BioCryst Pharmaceuticals by 14.5% in the 4th quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock worth $156,000 after buying an additional 2,453 shares during the last quarter. ClariVest Asset Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 1.6% in the 1st quarter. ClariVest Asset Management LLC now owns 234,898 shares of the biotechnology company’s stock worth $1,913,000 after buying an additional 3,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of BioCryst Pharmaceuticals by 6.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 71,800 shares of the biotechnology company’s stock worth $585,000 after buying an additional 4,151 shares during the last quarter. Institutional investors own 91.98% of the company’s stock.

Shares of BCRX stock traded down $0.05 on Friday, hitting $3.43. The stock had a trading volume of 14,980 shares, compared to its average volume of 4,577,449. The company has a market capitalization of $377.26 million, a PE ratio of -3.51 and a beta of 2.14. The company has a current ratio of 1.77, a quick ratio of 1.76 and a debt-to-equity ratio of 2.38. BioCryst Pharmaceuticals has a 52-week low of $2.80 and a 52-week high of $9.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). The business had revenue of $5.89 million during the quarter, compared to the consensus estimate of $2.92 million. BioCryst Pharmaceuticals had a negative net margin of 472.12% and a negative return on equity of 223.34%. Equities research analysts predict that BioCryst Pharmaceuticals will post -1.21 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: P/E Growth (PEG)

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.